VivoSeq
Ophthalmology

Dry Eye Syndrome

63

Pipeline Programs↗

2

Active Trials↗

29

Companies Involved↗

Dry Eye Syndrome is a moderately active landscape with 63 programs across 29 companies. The most active players are Eleven Biotherapeutics, Vitae Pharmaceuticals Inc., an Allergan affiliate, Kissei Pharmaceutical Co., Ltd.. 18 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

98/100

Attrition Rate

2/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eleven Biotherapeutics

1 program

Phase 1V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 1K

Kissei Pharmaceutical Co., Ltd.

2 programs

Phase 2S

Samjin Pharmaceutical Co., Ltd.

2 programs

Phase 2A

Avizorex Pharma, S.L.

1 program

Phase 2A

Aldeyra Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Rebamipide

Otsuka

Tetracycline

Wyeth-Lederle Vaccines

Loteprednol Etabonate

Bausch & Lomb Incorporated

Cyclosporine Emulsion

Vanderbilt-Ingram Cancer Center

Umbilical Cord Serum Eyedrops

Chonnam National University Hospital

Phase 12

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

EBI-005-2

Eleven Biotherapeutics

Phase 220

Canakinumab

Novartis

Secukinumab

Novartis

Cyclosporin a

Novartis

SJP002

Samjin Pharmaceutical Co., Ltd.

KCT-0809

Kissei Pharmaceutical Co., Ltd.

Phase 315

Brimonidine Tartrate

AbbVie

RGN-259

ReGenTree, LLC

Cyclosporine a

Novartis

Sodium Hyaluronate

Sanofi

Restasis

Aurinia Pharmaceuticals

Approved18

Naltrexone

Teva

Varenicline

Prism Pharmaceuticals

Tobramycin

Viatris Specialty LLC

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Cyclosporine

Novartis

Analysis

Modality Breakdown

98%

Small molecule

79 of 81 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody22%

Small molecule leads; the ring shows all 81 classified programs, each share of the total. Modality classified for 100% of 82 pipeline programs.

Analysis

Trial Status

64

clinical trials

Completed57 · 89%
Unknown status4 · 6%
Recruiting2 · 3%
Withdrawn1 · 2%

Clinical Trials

Trial Activity

64 trials

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients
Recruiting·AAJU Pharm Co., Ltd.·Phase 3·NCT06291194·396 enrolled
Exosomes Proteomic for Sjogren's Syndrome and Dry Eye Syndrome
Recruiting·TTaipei Veterans General Hospital, Taiwan·N/A·NCT06771427·220 enrolled
YM-101 Eye Drops in the Treatment of Dry Eye Syndrome
Completed·EEye & ENT Hospital of Fudan University·Phase 1·NCT06792903·30 enrolled
Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome
Completed·SSIFI SpA·Phase 2·NCT04645446·96 enrolled
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
Completed·RReGenTree, LLC·Phase 2/3·NCT02597803·317 enrolled
A Study of KCT-0809 in Patients With Dry Eye Syndromes
Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT01211951·160 enrolled
Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
Completed·SSamjin Pharmaceutical Co., Ltd.·Phase 2·NCT03723798·172 enrolled
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
Completed·National Eye Institute (NEI)·Phase 2·NCT00001731·30 enrolled
Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome
Completed·HHuons Co., Ltd.·Phase 2·NCT02917512·114 enrolled
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
Completed·BBausch & Lomb Incorporated·Phase 2/3·NCT00198536·159 enrolled
To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome
Completed·HHuons Co., Ltd.·Phase 3·NCT06388070·297 enrolled
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Completed·AAldeyra Therapeutics, Inc.·Phase 2·NCT03162783·51 enrolled
Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome
Completed·—·N/A·NCT00442273
Safety and Efficacy of BRM421 for Dry Eye Syndrome
Completed·BBRIM Biotechnology Inc.·Phase 2·NCT03066219·157 enrolled
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Completed·KKissei Pharmaceutical Co., Ltd.·Phase 2·NCT01890941
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)